Patent 6204245 Issued on March 20, 2001. Estimated Expiration Date: September 17, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/11, Monocyclic514/90, Chalcogen in the six-membered hetero ring514/99, Oxygen containing hetero ring514/165, Aspirin per se (i.e., 2-(acetyloxy)benozic acid)514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/180, 9-position substituted514/184, Heavy metal containing (including salts)514/249, 1,4-diazine as one of the cyclos514/263.32, Nitrogen containing hetero ring in the perservative, stabilizer, or additional active ingredient514/263.34, Chalcogen bonded directly to the 2-and 6- positions of the purine ring system (e.g., theophylline, etc.)514/291, Plural hetero atoms in the tricyclo ring system514/313, Nitrogen, other than as nitro or nitroso, attached directly to the six membered hetero ring by nonionic bonding514/404, Divalent chalcogen or acyclic nitrogen double bonded directly to ring carbon of the diazole ring, or tautomeric equivalent514/411, Tricyclo ring system having the five-membered hetero ring as one of the cyclos514/420, Indomethacine per se or ester thereof514/495, Gold or silver514/562, Sulfur nonionically bonded514/567, Benzene ring nonionically bonded514/569, Polycyclo ring system514/570, Carboxy or salt thereof only attached indirectly to the benzene ring514/649Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain
The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one immunosuppressive agent. The methods are particularly useful for prophylactic and therapeutic treatment of narcolepsy or isolated cataplexy.
Other References
Aldrich, M., "Narcolepsy and Related Disorders," Sleep Medicine, Chapter 10, pp. 152-174; Oxford University Press, New York, NY U.S.A. (1999)
Aldrich, M. S., "Narcolepsy," New Eng. J. Med., 323389-394 (1990)
Aldrich, M. S., "Narcolepsy," Neurology, 42(Suppl. 6):34-43 (1992)
Aldrich, M. S., "The Neurobiology of Narcolepsy," TINS, 14(6):235-239 (1991)
Aldrich, M. S., "Diagnostic aspects of narcolepsy," Neurology, 50(suppl. 1):S2-S7, 1991
Baker et al., "Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance," Brain Mechanisms of Sleep, edited by McGinty et al.; New York: Raven Press, pp. 199-233 (1985)
Behar et al., "A New DRBI*12022 Allele (DRBI*12022) found in association with DQA1*0102 and DQB1*0602 in two black narcoleptic subjects," Immunogenetics, 41:52 (1995)
Billiard, M., "Narcolepsy, Clinical Features and Aetiology," Ann. Clin. Res., 17:220-226 (1985)
Billiard et al., "Elevated antibodies to streptococcal antigens in narcoleptic subjects," Sleep Res., 18:201, (1989), abstract only
Broughton et al., "Psychosocial impact of narcolepsy," Sleep, 17:S45-S49 (1994)
Cadieux et al., "Pharmacologic and Psychotherapeutic Issues in Coexistent Paranoid Schizophrenia and Narcolepsy: Case Report," J. Clin. Psychiatry., 46:191-193 (1985)
Cederberg et al., "Breeding history of the Stanford colony of narcoleptic dogs," Vet. Rec., 142:31-36 (1998)
Chemelli et al., "Narcolepsy in orexin Knockout Mice: Molecular Genetics of Sleep Regulation," Cell, 98:437-451 (1999)
Delashaw et al., "Cholinergic Mechanisms and Cataplexy in Dogs," Exp. Neurology, 66:745-757 (1979)
Douglass et al., "Three Simultaneous Major Sleep Disorders," Can. J. Psychiatry, 32(1):57-60 (1987)
Douglas et al., "Florid Refractory Schgizophrenias That Turn Out to Be Treatable Variants of HLA-Associated Narcolepsy," J. Nerv. Ment. Dis., 179(1):12-17 (1991)
Douglass et al., "Monozygotic twins concordant for the narcoleptic syndrome," Neurology, 39(1):140-141 (1989)
Erlich et al., "Narcolepsy: A Neuropathologic Study," Sleep, 9:126-132 (1986)
Foutz et al., "Genetic Factors in Canine Factors in Canine Narcolepsy," Sleep, 1(4):413-421 (1979)
Fredrickson et al., "CSF immune variables in patients with narcolepsy," Acta. Neurol. Scan., 81:253-254 (1990)
Gaiser et al., "Evidence for an autoimmune etiology in canine narcolepsy," Sleep Res., 18:230 (1989) abstract only
Gibson et al., "HLA and Schizophrenia: Refutation of Reported Associations with A9 (A23/A24), DR4, and DQ댡*0602," Am. J. Med. Genetics, 88:416-421 (1999)
Green et al., "Narcolepsy Signs, Symptoms, Differential Diagnosis, and Management," Arch. Fam. Med., 7:472-478 (1998)
GroBkopf et al., "Potential role for the narcolepsy-anmd multiple sclerosis-associated HLA allele DQB1*0602 in schizophrenia subtypes," Schizophrenia Research, 30:187-189 (1998)
Guilleminault et al., "Investigations into the neurologic basis of narcolepsy," Neurology, 50(Suppl. 1):S8-S15 edited by Fry, J.M. (1998)
Guilleminault, C., "Narcolepsy Syndrome", Principles and Practice of Sleep Medicine, 2hu ndedition, pp. 549-561, 1993
Guilleminault et al., "Prazosin Contraindicated in Patients with Narcolepsy," The Lancet, 2(8609):511 (1988)
Hinze-Selch et al., "In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls," Neurology, 50:1149-1152 (1998)
Honda et al., "Genetic Aspects of Narcolepsy," in Handbook of Sleep Disorders, edited by M. Thorpy; (Marcel Dekket, Inc., New York, NY) (1990), pp. 217-234
Honda et al., "HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy," Sleep, 9(1):133-142 (1986)
Hublin et al., "The prevalence of narcolepsy: and epidemiological study of the Finnish twin cohort," Ann. Neurol., 35(6):709-716 (1994)
Jacob et al., "Heritable major histocompatibility complex Class II-associated differences in production of tumor necrosis factor and relevance to genetic predisposition to systemic lupus erythematosus," PNAS, 87:1233-1237 (1990)
Kaitin et al., "Evidence for excessive sleepiness in canine narcoleptics," Electroencheph. Clin. Neurophysiol., 64:447-454 (1986)
Kanbayashi et al., "Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy," Neuroreport, 7(12):1881-1886 (1996)
Kilduff et al., "Immunosuppression with Cyclosporine as a Treatment for Canine Narcolepsy," Sleep Research, 16:369 (1987) abstract
Klippel et al., Rheumatology, second edition, cover page and table of contents, London:Mosby (1998)
Krueger et al., "Cytokines in sleep regulation," Sleep and sleep disorders: from molecule to behavior, edited by Hayaishi and Inoue; pp. 261-277; Tokyo: Academic Press (1997)
Langdon et al., "Immune factors in narcolepsy," Sleep, 9(1):143-148 (1986)
Lin et al., "The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene," Cell, 98:365-376 (1999)
Matsuki et al., "No male segregation distortion of DR2 Haplotypes in Japanese narcoleptic patients," Human Immunology, 23:23-26 (1988)
Matsuki et al., "HLA in Narcolepsy in Japan," chapter 3 from HLA in Narcolepsy, edited by Honda and Juji; pp. 58-76; New York: Springer Verlag (1988)
Matsuki et al., "DQ (rather than DR) genme marks susceptibility to narcolepsy," Lancet, 339:1052 (1992)
Mignot et al., "Genetic linkage of autosomal recessive canine narcolepsy with a μ immunoglobulin heavy-chain switch-like segment," PNAS, 88:3475-3478 (1991)
Mignot, E. et al., "DQBI*0602 and DQA1*0102 (DQ1) Are Better Markers Than Dr1 for Narcolepsy in Caucasian and Black Americans," Sleep, 17:S60-S67 (1994)
Mignot, E., "Genetic and familial aspects of narcolepsy," Neurology, 50(2)(Suppl 1):S16-S22 (1998)
Mignot et al., "Effect of 댑-adrenoceptors blockade with prazosin in canine narcolepsy," Brain Res., 444:184-188 (1988)
Mignot, E. et al., "Narcolepsy and immunity," Adv. Neuroimmunol., 5:23-37 (1995)
Mignot, E. et al., "Canine cataplexy is preferentiallyt controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers," Psychopharmacology, 113:76-82 (1993)
Mignot, E. et al., "Nocturnal Sleep and Daytime Sleepiness in normal Subjects with HLA-DQB1*0602," Sleep, 22(3):347-352 (1999)
Mitler, M. M. "Toward an animal model of narcolepsy-cataplexy," chapter 24 from Narcolepsy, edited by Guilleminault, Dement and Passouant; pp. 387-409; New York: Spectrum Publications, Inc. (1975)
Mitler et al., "Narcolepsy Diagnosis, Treatment, and Management," Psych. Clin. N. Amer., 10(4):593-606 (1987)
Mitler, M. M. et al., "treatment of Narcolepsy with Methamphetamine," Sleep, 16(4):306-317 (1993)
Mitler, M. M., "Evaluation of Treatment Wioth Stimulants in Narcolepsy," Sleep, 17:S103-S106 (1994)
Montplaisir et al., "Streptococcal antibodies in narcolepsy and idiopathic hypersoimnia," Sleep Res., 18:271 (1989) abstract only
Motoyama et al., "Restriction fragment length polymorphism in canine narcolepsy," Immunogenetics, 29:124-126 (1989)
Mueller-Eckhardt et al., "Is there an infectious origin of narcolepsy?," The Lancet, 424 (1990)
Nishino, S. et al., "Desmethyl Metabolites of Serotonergic Uptake Inhibitors Are More Potent for Supressing Cannine Cataplexy Than Their Parent Compounds,"Sleep, 16:706-712 (1993)
Nishino, S. et al., "Pharmacological aspects of human and canine narcolepsy," Prog. Neurobiol., 52:27-78 (1997)
Opp et al., "Interleukin-10 (cytokine synthesis inhibitory factopr) acts in the central nervous system of rats to reduce sleep,"J. Neuroimmunol., 60:165-168 (1995)
Pollmacher et al., "DR-2 Positive monizygotic twins discordant for narcoepsy," Sleep, 13(4):336-343 (1990)
Robinson et al., "Narcolepsy," chapter 25 from Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects, edited by Chokroverty, S.; Butterworth Heinemann Boston, MA U.S.A.(1999) pp. 427-440
Rubin et al., "HLA-DR2 association with excessive somnolence in narcolepsy does not generalize to sleep apnea and is not accomplanied by systemic autoimmune abnormalities," Clin. Immunol. Immunbopathol., 49:149-158 (1988)
Siegel, J.M. et al., "Neuronal degeneration in canine narcolepsy," J. Neuroscience, 19(1):248-257 (1999)
Sinha et al., "Autoimmune Diseases: The Failure of Self Tolerance," Science, 248:1380-1388 (1990)
Stein et al., "Glucocorticoids," chapter 50 from Texbook of Rheumatology, edited by Kelly et al.; pp. 787-803 (1997)
Tafti et al., "Major histocompatibility Class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.," J. Neurosci., 16(15):4588-4595 (1996)
Vgnotzas, A. N. et al., "Sleep and It's Disorders," Annu. Rev. Med., 50:387-400 (1999)
Yoss et al., "Narcolepsy in children," Pediatrics, 25:1025-1033 (1960
September 17, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
